Orthofix International Announces Third Quarter Results And Additional Debt Payment Ahead of Scheduled Maturity

  • Q309 sales totaled $135.1 million, up 4% from Q308; up 7% on a constant currency basis
  • Sales of spinal implants & biologics were up 10%, to $28.5 million, vs. prior year; sales of spine stimulation products grew 12%, to $39.6 million
  • Sales in the orthopedic business decreased 2%, but increased 6% on a constant currency basis
  • Sales in the sports medicine business grew 4% in total, to a record $24.7 million; U.S. sales increased 6%
  • Consolidated gross margin improved to 76.3%; operating margin increased to 13.1%
  • Q309 reported net income was $0.36 per diluted share; excluding certain items, adjusted net income was $0.44 per diluted share
  • The Company made an additional $5 million debt payment ahead of schedule maturity in October


Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *